What is First Light Diagnostics?
First Light Diagnostics is at the forefront of developing and commercializing advanced diagnostic products designed for the rapid and sensitive detection of life-threatening infections. Leveraging proprietary single-cell and single-molecule detection technology, the company aims to provide diagnostic solutions that combine the accuracy of laboratory tests with enhanced speed, cost-effectiveness, and user-friendliness. Their innovative approach seeks to significantly improve patient outcomes, reduce healthcare expenditures, and combat the spread of antibiotic resistance by enabling earlier and more precise antibiotic selection.
How much funding has First Light Diagnostics raised?
First Light Diagnostics has raised a total of $7.1M across 4 funding rounds:
Private Equity
$811K
Unspecified
$4.3M
Debt
$1M
Debt
$1M
Private Equity (2016): $811K, investors not publicly disclosed
Unspecified (2019): $4.3M led by BARDA
Debt (2020): $1M supported by PPP
Debt (2021): $1M featuring PPP
Key Investors in First Light Diagnostics
PPP
Public-Private Partnership
BARDA
BARDA (Biomedical Advanced Research and Development Authority) has provided significant unspecified funding, suggesting a strategic interest in advancing technologies critical for public health preparedness and response.
What's next for First Light Diagnostics?
With substantial enterprise-level backing and a recent strategic investment, First Light Diagnostics is poised to accelerate the commercialization of its breakthrough diagnostic platforms. The company's focus on addressing critical healthcare challenges, such as early infection detection and antibiotic resistance, positions it for significant growth. Future endeavors will likely involve expanding market reach, further refining its technology, and forging strategic partnerships to integrate its solutions into clinical workflows, thereby reinforcing its role in modern infectious disease management and antimicrobial stewardship.
See full First Light Diagnostics company page
